Company news

Arrowhead Pharmaceuticals, Inc. news in 2025

Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

December 22, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 14, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

December 7, 2025

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

December 1, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

November 30, 2025

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

November 24, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

November 23, 2025

ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS…

November 19, 2025

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 17, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 5, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

November 3, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 20, 2025

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

October 6, 2025

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 10, 2025

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 9, 2025

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 1, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 26, 2025

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

August 12, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

August 6, 2025

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

July 31, 2025

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

July 27, 2025

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

July 22, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

July 20, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 7, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

June 22, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

June 1, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 28, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 11, 2025

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 6, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

April 29, 2025

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

April 14, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

March 9, 2025

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

March 5, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

February 27, 2025

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

February 24, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

February 9, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

February 9, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

January 21, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

January 16, 2025

Calls in 2025

Decks in 2025